Conference Correspondent

Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Physician, Epidemiologist, Researcher, and Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York.
In the long-term, phase 1b/2 PCYC-1102 clinical trial, single-agent ibrutinib, the first FDA-approved once-daily Bruton’s tyrosine kinase inhibitor, showed efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma (SLL), including patients with deletion (del)17p.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) occur mainly in older patients, who are likely to have several comorbidities and who often are unable to receive aggressive drug therapies, such as alkylating drugs, which are typically used for patients with CLL or SLL.
Elderly patients with chronic lymphocytic leukemia (CLL) and younger patients with comorbidities often receive treatment with chlorambucil despite the relative low response rates.
In 2016, approximately 18,960 Americans were estimated to be diagnosed with chronic lymphocytic leukemia (CLL), and 4660 were estimated to die from the disease.
It is estimated that 18,960 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in 2016, and 4660 deaths.
Inpatient chemotherapy is often considered a financial loss, and according to Ali McBride, PharmD, MS, BCPS, BCOP, Clinical Coordinator, Hematology/Oncology, The University of Arizona Cancer Center, Tucson, transitioning chemotherapy to the outpatient setting can be beneficial to patients and providers.
Targeted therapy in the management of non–small-cell lung cancer is discussed.
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL.
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented.
Page 7 of 28
Results 61 - 70 of 273